

![]() |
Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE's STAT-Net |
|
Authors | ![]() | |
Published in | Intensive care medicine. 2017, vol. 43, no. 7, p. 1002-1012 | |
Abstract | In this era of rising antimicrobial resistance, slowly refilling antibiotic development pipelines, and an aging population, we need to ensure that randomized clinical trials (RCTs) determine the added benefit of new antibiotic agents effectively and in a valid way, especially for severely ill patients. Unfortunately, universally accepted endpoints for the evaluation of new drugs in severe infections are lacking. | |
Identifiers | PMID: 28466147 | |
Full text | ||
Structures | ||
Research group | Epidémiologie et contrôle de la résistance aux antibiotiques (866) | |
Citation (ISO format) | TIMSIT, Jean-François et al. Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE's STAT-Net. In: Intensive Care Medicine, 2017, vol. 43, n° 7, p. 1002-1012. doi: 10.1007/s00134-017-4802-4 https://archive-ouverte.unige.ch/unige:99523 |